USFDA issues import alert to Ranbaxy Laboratories’ Mohali unit

16 Sep 2013 Evaluate

Ranbaxy Laboratories, India’s largest pharmaceutical company, has been issued import alert by US Food & Drug Administration (USFDA) on September 13 for its Mohali unit. The import alert was issued due to non-compliance with drug good manufacturing practices (GMPs).

The Mohali unit was already issued Form 483 in May 2012 signifying that there were certain manufacturing practices, which the USFDA had already pointed out and the company had time to comply the problems, which USFDA had brought up. However, since Ranbaxy could not comply to those issues the 483 has now converted to an import alert.

Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×